Garry Neil, MD, is Corporate Vice President, Science and Technology, Johnson & Johnson. Garry joined J&J in 2002 as Senior Vice President of Drug Development at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD). In 2005, Garry became President of J&JPRD, and in 2006, was promoted to Group President. Before joining J&JPRD, he held senior-level positions with Astra Merck Inc., Astra Pharmaceuticals, Astra Zeneca and Merck KGaA. He has also held academic posts at the Ludwig Institute for Cancer Research, the University of Toronto, the University of Iowa College of Medicine and the University of Pennsylvania (adjunct).
Garry has written over 50 articles and book chapters. He is a Fellow of the American College of Physicians, a Fellow of the American College of Gastroenterology, a member of the American Association of Immunologists, and the Society for Clinical Trials. He is also a member of the Board of the J&J Development Corporation and is J&J’s representative to, and Chairman of, the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee, Chairman of the PhRMA Foundation Board, Chairman of the Scientific Advisory Board of the Center for Advanced Biotechnology and Medicine (Rutgers), and a member of the Executive Committee of the Biomarkers Consortium of the Foundation for the National Institutes of Health.
He holds a Bachelor of Science degree from the University of Saskatchewan and a medical degree from the University of Saskatchewan College of Medicine and completed his postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. He also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic.